- Home
- QLYS vs TOVX Comparison
QLYS vs TOVX Comparison
Compare QLYS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLYS
- TOVX
- Stock Information
- Founded
- QLYS 1999
- TOVX 2001
- Country
- QLYS United States
- TOVX United States
- Employees
- QLYS N/A
- TOVX N/A
- Industry
- QLYS Computer Software: Prepackaged Software
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- QLYS Technology
- TOVX Health Care
- Exchange
- QLYS Nasdaq
- TOVX Nasdaq
- Market Cap
- QLYS 5.7B
- TOVX 3.5M
- IPO Year
- QLYS 2012
- TOVX 2006
- Fundamental
- Price
- QLYS $140.73
- TOVX $1.14
- Analyst Decision
- QLYS Hold
- TOVX Strong Buy
- Analyst Count
- QLYS 18
- TOVX 1
- Target Price
- QLYS $154.19
- TOVX $6.00
- AVG Volume (30 Days)
- QLYS 298.7K
- TOVX 96.3K
- Earning Date
- QLYS 02-05-2025
- TOVX 11-12-2024
- Dividend Yield
- QLYS N/A
- TOVX N/A
- EPS Growth
- QLYS 22.85
- TOVX N/A
- EPS
- QLYS 4.53
- TOVX N/A
- Revenue
- QLYS $592,950,000.00
- TOVX N/A
- Revenue This Year
- QLYS $11.24
- TOVX N/A
- Revenue Next Year
- QLYS $7.62
- TOVX N/A
- P/E Ratio
- QLYS $31.07
- TOVX N/A
- Revenue Growth
- QLYS 9.66
- TOVX N/A
- 52 Week Low
- QLYS $119.17
- TOVX $1.14
- 52 Week High
- QLYS $206.25
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- QLYS 38.20
- TOVX 36.15
- Support Level
- QLYS $140.19
- TOVX $1.23
- Resistance Level
- QLYS $159.73
- TOVX $1.21
- Average True Range (ATR)
- QLYS 3.45
- TOVX 0.07
- MACD
- QLYS -2.42
- TOVX 0.01
- Stochastic Oscillator
- QLYS 2.76
- TOVX 0.00
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.